AstraZeneca Notches Back-to-Back Late-Stage Wins in Lung Cancer

AstraZeneca reported positive data from both the Phase III ADAURA trial studying Tagrisso (osimertinib) and the Phase III AEGEAN studying Imfinzi (durvalumab) in NSCLC patients.